UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/820,269	04/08/2004	Torsten Schulz	15111.0081	8565
88859 Steptoe & Johns	7590 01/21/201 son LLP	EXAMINER		
1330 Connecticut Avenue, NW			LUNDGREN, JEFFREY S	
Washington DC, DC 20036			ART UNIT	PAPER NUMBER
			1639	
			MAIL DATE	DELIVERY MODE
			01/21/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
Office Action Summary		10/820,269	SCHULZ ET AL.			
		Examiner	Art Unit			
		JEFFREY S. LUNDGREN	1639			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)[\	Responsive to communication(s) filed on 22.0	ctober 2009				
·	Responsive to communication(s) filed on <u>22 October 2009</u> . This action is FINAL . 2b) This action is non-final.					
′=	, 					
3)[
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims					
4)🛛	☑ Claim(s) <u>1-49</u> is/are pending in the application.					
	4a) Of the above claim(s) <u>25-43</u> is/are withdrawn from consideration.					
5)□	s) Claim(s) is/are allowed.					
· · · · · · · · · · · · · · · · · · ·	6)⊠ Claim(s) <u>1-24 and 44-49</u> is/are rejected.					
· ·	Claim(s) is/are objected to.					
-	Claim(s) are subject to restriction and/o	r election requirement				
٥/ك	and data journal to receive manage	. oloculott toquilottici				
Applicati	on Papers					
9)☐ The specification is objected to by the Examiner.						
10)	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
		·				
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da				
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application 6) Other:						

DETAILED ACTION

Page 2

Status of the Claims

Claims 1-49 are pending in the instant application; claims 25-43 are withdrawn as being directed to a non-elected invention; claims 1-24 and 44-49 are the subject of the Office Action below.

Claim Rejections - 35 USC § 112 - New Matter

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The rejection of claims 1-24 and 44-49, under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement for the introduction of new matter, is maintained. The claims contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention.

The rejection of claims 1 and 44, and all claims dependent therefrom, as having new matter for introducing the phrase "the volume of the chamber space being coextensive with the volume of the enclosed recess." <u>is maintained</u>.

The rejection of claim 47, and all claims dependent therefrom, as having new matter for introducing the phrases: "displacement distance"; "continuous wall"; "first thickness"; and "second thickness" is maintained.

Applicants generally allege that they have support for the disputed limitations in their disclosure as originally filed. Applicants suggest that support from the specification can be found on a certain few paragraphs and in Figure 2:

"With the above in mind, support for the phrase "the volume of the chamber space being coextensive with the volume of the enclosed recess" may be found, for example, at 12-13, 30-31, and at Fig. 2. In conjunction with the reference number legend at pages 30-31 of the specification, Fig. 2 illustrates a base element 400, lid element 200, and a sealing, elastic, repeatedly puncturable intermediate element 300. Recess 301 is enclosed

Application/Control Number: 10/820,269

Art Unit: 1639

in intermediate element 300 and defines a reaction space. Paragraph 0047, at pages 12-13, also explains that "intermediate element 300 is characterized in that it has an enclosed recess 301. Due to this recess 301 ... defines the volume of the reaction space (provided by 301)... both the geometry and the volume of the reaction space may be varied." (emphasis added). The figure and the description considered together illustrate (i.e., provide a written description of) a device in which the volume of a chamber space is coextensive with the volume of an enclosed recess."

Page 3

Reply, page 12.

The Examiner disagrees. Neither the description as referenced, nor Figure 2 and the particular elements of the figure, provides a literal or reasonable description that is supportive of the claim limitations that are indicated to be new matter. There is nothing in the specification or figures that would lead one of ordinary skill in the art to conclude that Applicants had described a chamber space "being coextensive with the volume of the enclosed recess." Instead, this limitation is derived after the fact by Applicants. There is not nearly enough detail in Applicants' figure to find support for the chamber space being coextensive with the volume of the enclosed recess. Moreover, the specification does not even use the term "coextensive".

The same findings are true for the disputed limitations "displacement distance"; "continuous wall"; "first thickness"; and "second thickness" as they are used in combination in claim 47. Again, Applicants have selectively chosen to create an arrangement of claim limitations that was not reasonably described at the time the invention was filed. None of the Figures or the specification supports Applicants assertions.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. § 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 10/820,269 Page 4

Art Unit: 1639

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. § 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.

- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

The rejection of claims 1-24 and 44-49 under 35 U.S.C. 103(a) as being unpatentable over Blackburn *et al.*, U.S. Patent Application Publication No. 2006/0160205 A1, published July 20, 2006; in view of Ehricht *et al.*, U.S. Patent Application Publication No. 2002/0150933, published on October 17, 2002; Lipshutz *et al.*, U.S. Patent No. 5,856,174, issued on January 5, 1999; and Paul *et al.*, U.S. Patent Application Publication No. 2003/0091477 A1, published on May 15, 2003, is maintained.

Applicants traverse the rejection and allege that none of the references teach each of "[t]he lid element, the intermediate element and the base element are held together between the two fixed holding elements to form a closed optically translucent chamber having a chamber space. The volume of the chamber space is coextensive with the volume of the enclosed recess. See claim 1." (Reply, page 13).

With the limitation of "the chamber space" being coextensive with "the volume of the enclosed recess" it is noted that the only possible claim construction would be that these two volumes are one and the same. The term "coextensive" generally means to share the same boundaries – the only way that a three-dimensional volume could share the same boundaries is if the volumes were the same.

This is in fact what is shown in the teaching of Paul, as explained below with reference to the figure provided. Paul teaches many "sealing elements" not just the septum that Applicants are referencing. For example, see drawing elements 330 and 331, wherein these two seal form an enclosed recess "coextensive" with the chamber space. The rejection is maintained.

Reiterated Rejection:

The claims are directed towards a device for holding a substance library carrier, comprising a lid element having a detection surface with a substance library on its underneath

side and being optically translucent at least in an area of the detection surface, a sealing intermediate element having an enclosed recess, and a base element being optically translucent at least in an area of the detection surface of the lid element, wherein the lid, intermediate element and base together form an optically translucent chamber having a chamber space, and variations thereof, wherein the lid element the intermediate element and the base element are held together between tow fixed holding elements. Claims 44 and 45 are drawn to a device for filling a second device as described in claim 1.

Blackburn et al., US 2006/0160205 A1, throughout the publication, and at p. 7, para [0080]-[0082] teach cartridges comprising a reaction chamber that contains a biochip array, i.e., library. Blackburn at para [0088] teach inlet ports comprising a seal, and wherein the seal comprises a gasket, reading on a sealing intermediate, through which a pipette or syringe can be pushed. Blackburn et al., at para [0132] teaches a biochip substrate that can serve as one half of the reaction chamber, with the array on the inside, and the housing serving as the other half. Blackburn at para [0134] teaches a reaction chamber entirely of plastic or glass. Blackburn at para [0136] teaches cartridges that comprise a lid, and wherein the lid can take on a wide variety of configurations.

For claims 44 and 45, the device (for filling a second device) wherein the body contains recesses for a filling unit, a ventilation unit and the second device, and wherein the recesses are arranged such that the sample chamber of the second device may be loaded and vented through puncturing of the intermediate element from its side. In Figs 1B and 1D, (see column 1, paragraph 10), it is shown an outlet port is positioned at the top and vents outside. Also shown in Figure 1C, the outlet port is located to the side of the chamber. Blackburn et al., also teaches in column 5, paragraph 62, the chips can include reaction chamber with inlet and outlet ports for the introduction and removal of reagents. In column 8, paragraph 91 and column 9, paragraph 91, Blackburn teaches the biochip or cartridge may have a vent. In column 8, paragraphs 88 and 89, Blackburn et al., discloses the inlet port may comprise a seal to prevent or reduce the evaporation of the sample or reagents from the reaction chamber, and the seal comprises a gasket, or valve through which a pipette or syringe can be pushed (thus puncturing the layer); also, a systems is used wherein the exit port vents to the inlet port, preferably above the point of loading. In column 8, paragraph 91, it is taught by Blackburn et al., that the biochip cartridge is

designed to include one or more loading ports or valves that can be closed off or sealed after the sample is loaded and the biochip my have a vent. It is also shown, in column 3, paragraph 30, that the ventilation unit also comprises a second cannula. In this example, the use of a pipette tip can serve as a second cannula for loading a sample into a sample introduction chamber (loading into a recess as in claim 45; see Figures 15A and 15C). Finally, in column 11, paragraph 131, Blackburn et al., disclose that the cartridge or biochip comprises a sealing and/or venting mechanism to prevent the cartridge from exploding or to prevent leakage.

Blackburn at para [0106] teaches off chip pumps, reading on the first device of claim 44. Blackburn at Fig. 15C teaches a first device containing recesses for a filling unit. The pipette tip also would act as a ventilation unit to allow infusion of liquid.

Blackburn et al., at para [0129], teach a variety of reaction chamber geometries to allow for smooth loading of the reaction chambers.

Blackburn does not explicitly teach a lid with a substance library on its underneath side and a lid and base element being optically translucent at least in an area of the detection surface, or the newly introduced claim elements of two fixed holding elements holding the lid element, intermediate element, and the base element.

Ehricht et al., throughout the publication, column 4, paragraph 55-58, and column 5, paragraphs 61-62) disclose a device (see Figure 1) for duplicating and characterizing nucleic acids, consists of a chamber body and a chamber support. Ehricht et al., also disclose a device for holding a chip (e.g. a nucleic acid chip or substance library see column 4, paragraph 55).

Ehricht also discloses two holding elements that are fixable with each other (for example, see figure 1 wherein the "two sides" of element 42 represent "holding elements" and they are "fixed" at a distance that is equal to the length of element 2. Ehricht also discloses an element that is optically translucent at least in an area of the detection surface (see column 4, paragraphs 56 and 58). Ehricht et al., further disclose a sealing intermediate having an enclosed recess (column 3 paragraph 24; column 4, paragraph 55; and column 5, paragraph 68), a chamber body and chamber support wherein the chamber body is provided with a bearing surface via which chamber body is in a sealing connection with chamber support, so that a sample chamber is formed. Ehricht et al., disclose that the lid element, the intermediate element and the base

element together form an optically translucent chamber having a chamber space (see figures 1-3).

For claim 2, Ehricht et al., discloses a device wherein the base element comprises an integrated heating-temperature sensor device. Ehricht et al., teaches (see column 3, paragraphs 31-32) that by means of the device, the PCR and the hybridization parallel to chip-bound nucleic acid are spatially combined in a temperature controllable and throughput controllable cell (chamber). Ehricht et al., also discloses heating and cooling elements which are placed on a chamber support together with temperature sensors and electrodes, which chamber support holding the chamber and being in a heat-conducting contact with same through the chamber bottom.

For claim 3, a device wherein the base element comprises monocrystalline silicon, Ehricht et al., discloses in column 4, paragraph 58 that the chip consists in a known manner of an optically transparent support, the material of which, for example, can be silicon or glass.

For claim 4, a device wherein the lid element comprises Borofloat 33, Ehricht discloses (see column 4, paragraph 57) the chip can preferably be made of borofloat glasses.

For claim 7, a device wherein the recess defines a geometrical form of the chamber space. The examiner concludes that the geometrical form is meant to represent the arrangement of the library on the chip with respect to the recess. Ehricht et al., discloses (see abstract and column 4, paragraph 56) that the detection surfaces of the chip (in the form of spots) is mounted in the chamber body with a recess whose edge sealing holds an optically transparent chip consisting of individual spots on a detection surface in such a way that the detection surfaces in the form of spots are positioned opposite and facing the surface of the chamber support by edge of the chamber support. Finally, column 5, paragraph 69 (Figure 3) discloses the recess across which detection surfaces including spots of the chip is optically accessible.

For claim 8, wherein the chamber space may be filled free of air bubbles, Ehricht et al., discloses in column 6, paragraph 77 that contingent air bubbles can be discharged from capillary gap into gas reservoir of sample chamber.

For claim 10, a device wherein the chamber may be cooled, Ehricht et al, discloses in column 3, paragraph 31 that the device can be used for PCR, thus as a thermocycler which can ramp between various temperatures. Ehricht et al., also teaches that by means of the device,

PCR and hybridization parallel to chip-bound nucleic acid are spatially combined in a temperature-controllable and throughput controllable cell (chamber). In column 5, paragraph 63, Ehricht et al., also teaches that the heating elements can be preferably selected so that a fast heating and cooling of the liquid (in the capillary gap) is possible.

For claim 12, a device wherein the holding elements each comprise channels for cooling the chamber, Ehricht et al., discloses (see Fig 4 and column 5, paragraph 63) that the heating elements can be preferably selected so that a fast heating and cooling of the liquid in the capillary gap is possible. They further teach (Fig 4, column 5, paragraph 70) that the heating elements situated at the lower side of the (transparent) chamber support including conducting paths and connecting surfaces. Conducting paths are synonymous with channels.

For claims 18-24, a device which contains a protein, antibody, peptide, receptor/ligand, hormone, nucleic acid, DNA or RNA library, Ehricht et al., (see column 4, paragraph 57) disclose a chip that is preferentially functionalized by nucleic acid molecules, in particular by DNA or RNA molecules. However, the chips can likewise be functionalized by peptides and/or proteins such as, for example antibodies, receptors molecules, and pharmaceutically active peptides and/or hormones. Also, see the abstract where it teaches a device consists of a chamber body with a recess whose edge sealingly holds an optically transparent chip. Said chip holds nucleic acids (DNA or RNA) in individual spots on a detection surface.

Lipshutz et al., (US Patent 5,856,174 (5 January, 1999), throughout the patent and at col. 18, lines 5-19, teach reaction chambers incorporating a sealable closure or septum, through which a sample may be introduced or injected. Lipshutz at col. 11, teach detection of hybridization upon arrays using optical methods, such as epifluorescence confocal microscopy. Lipshutz at col. 12, lines 16-30, teach production of arrays by etching onto the same polymeric materials used for the fabrication of the body of their device.

Lipshutz et al., teaches in column 19, lines 20-29, a device for holding a substance library carrier having two holding elements that are fixable with each other and comprising a lid and base that are optically transparent in at least one area of detection and having a sealing intermediate element with an enclosed recess,; discloses the use of an oligonucleotide array (substance library carrier) as the bottom surface of a chamber. In column 27, lines 1-3; Lipshutz et al., disclose that the base unit may include a second surface which contacts the opposite

surface of the device from the first surface, or one surface is "fixable" with a second surface. The device is made up of multiple chambers and at least one chamber will typically have as at least one surface, a transparent window for observation or scanning. Having "at least one transparent surface" implies there can be two surfaces that are transparent. Therefore, it would have been obvious to place the second transparent surface in the base, especially if the windows are to be used for viewing and scanning because the standard is to perform those two functions from opposite sides of the substance library. In column 18, lines 1-4; Lipshutz et al., teaches that the body of the device incorporates reaction chambers that are connected in series. In Column 19, lines 59-64, Lipshutz also discloses that the chambers included in the device of the invention have a centralized geometry having a central chamber for gathering and distribution of a fluid sample to a number of separate reaction/storage/analytical chambers arranged around, and fluidly connected to the central chamber.

For claim 3, a device wherein the base element comprises monocrystalline silicon, in column 14, lines 35-45, the reference teaches the body of the device is generally fabricated using one or more of a variety of methods and materials suitable for microfabrication techniques. For example, the body of the device may comprise a number of planar members that may individually be injection molded parts fabricated from a variety of polymeric materials, or may be silicon, glass, or the like. In the case of crystalline substrates like silica, glass, or silicon, methods for etching, milling, drilling, etc., may be used to produce wells and depressions which makeup the various reaction chambers and fluid channels within the device.

For claim 9, a device wherein the chamber space is formed in the shape of a D, a new moon, or a sickle, Lipshutz, et al., teaches in column 14, lines 15-17; the body of the device may be embodied in any number of shapes depending upon the particular need. Thus, this anticipates a chamber space being formed in any shape.

For claim 10, the chamber may be cooled, Lipshutz et al., in column 2, line 55 teaches a chamber that can be temperature controlled. In column 19, lines 1-4; column 25, lines 6-8; column 27, 37-47, teach the device can be used for thermal cycling of the sample. One skilled in the art would know that this means rapid heating of cooling of the sample in a particular chamber to carry out an amplification reaction.

For claim 14, a device comprising a media connection for heating the chamber, and a media connection for cooling the chamber and a recess for receiving an injection apparatus, all of which are located on one side of the device, Lipshutz further discloses (see column 4, lines 40-45 and 55-64) chambers and components may also be included to provide reagents, buffers, sample manipulation, e.g., mixing, pumping, fluid direction (i.e. valves) heating and the like. It also discloses injecting the sample into the collection chamber through a sealable opening, e.g. an injection valve, or a septum. Alternatively, the device may be provided with a hypodermic needle integrated within the device and connected to the sample collection chamber.

Page 10


For claims 15-17, a device with is attached to a connector and may be operated fully automatically through the connector and which is attached to a manual filling station, Lipshutz et al, (see column 4, lines 16-45) discloses that the device will typically be one component of a larger diagnostic system that includes among other things a computer based interface for controlling the device. Furthermore, in Lipshutz, et al., (see column 5, lines 6-11) disclose that the reagents may generally be stored within the sample collection chamber of the device, or may be stored within a separately accessible chamber wherein the reagents may be added to or mixed. Finally, in column 5, lines 46-48, Lipshutz teach that the appropriate reagents may be incorporated within the [extraction] chamber or externally introduced.

For claims 44, 45 the device previously described above, and a second device wherein the sample chamber of the second device may be loaded and vented through puncturing of the intermediate element from its side. Lipshutz et al, (see column 4, lines 56-64) discloses the sample may be directly injected into the collection chamber through a sealable opening, e.g., an injection valve, or a septum. The device may also be provided with a hypodermic needle integrated within the device and connected to the sample collection chamber.

Paul teaches a system for performing hybridization assays is disclosed which has a cartridge for housing an array device. The cartridge may include a test fluid chamber for facilitating a substantially uniform flow of a test fluid mixture through the flow through device, and may include a fluidics station to deliver the test fluid mixture to the cartridge. The cartridge has a plurality of channels to receive fluids used in the performance of hybridization assays and to keep them separate (see *Abstract*), and considered a flow-through-chip (FTC). Figure 3 shows an exploded view of the FTC.

Application/Control Number: 10/820,269

Art Unit: 1639



In this view, at least elements 350 and 310 serve has fixed holding elements that hold lid elements, intermediate elements and base elements.

It would have been *prima facie* obvious, at the time the invention was made, for one of ordinary skill in the art to have made and used a device comprising a lid with a substance library on its underneath side and a lid and base element being optically translucent at least in an area of the detection surface; and another device for filling the aforementioned device as described in claim 1. One of ordinary skill in the art would have been motivated to make and use a device comprising a lid with a substance library on its underneath side and a lid and base element being optically translucent at least in an area of the detection surface because there is no difference between a base and a lid of the claimed invention, except that the lid has the library. The prior art reference of Lipshutz teaches and suggests the etching of an array into a portion of the

chamber, so that it may be considered that that portion would suggest the lid of the instant invention. Furthermore, Lipshutz and Ehricht teach and suggest translucent reaction chambers in order to detect binding using light microscopy, and Paul teaches the usefulness of a holding device to hold fixed optically transparent microarray chambers.

Common Ownership of Claimed Invention Presumed

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the Examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR § 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the Examiner to consider the applicability of 35 U.S.C. § 103(c) and potential 35 U.S.C. §§ 102(e), (f) or (g) prior art under 35 U.S.C. § 103(a).

Conclusions

No claim is allowable.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

If Applicants should amend the claims, a complete and responsive reply will clearly identify where support can be found in the disclosure for each amendment. Applicants should point to the page and line numbers of the application corresponding to each amendment, and provide any statements that might help to identify support for the claimed invention (e.g., if the amendment is not supported *in ipsis verbis*, clarification on the record may be helpful). Should Applicants present new claims, Applicants should clearly identify where support can be found in the disclosure.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Jeff Lundgren whose telephone number is 571-272-5541. The Examiner can normally be reached from 7:00 AM to 5:30 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Christopher Low, can be reached on 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Jeffrey S. Lundgren/

Primary Examiner, Art Unit 1639